Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 751-757

  Malo De Molina, R ^a   Mortensen, E M ^a   Restrepo, M I ^a   Copeland, L A ^a,b   Pugh, M J V ^a   Anzueto, A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Mortality; Pneumonia

Indexed keywords

CORTICOSTEROID;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; COMORBIDITY; FEMALE; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 77957855131     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00077509     Document Type: Article

References (52)

1. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
3. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207.
4. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
5. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
6. Calverley P, Pauwel R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
7. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD003794.
8. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
9. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
10. Kardos P, Wencket M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149.
11. Wedzicha JA, Carverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
12. Almirall J, Bolibar I, Balanzo X, et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13: 349-355.
13. Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. National Vital Statistics Reports 2001; 49: 1-113.
14. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163: 317-323.
15. Farr BM, Bartlett CL, Wadsworth J, et al. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000; 94: 954-963.
16. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-1216.
17. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28: 346-351.
18. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 2005; 20: 230-238.
19. Ruiz De Oña JM, Gómez Fernández M, Celdrán J, et al. Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification. Arch Bronconeumol 2003; 39: 101-105.
20. Pugh MJV, Joyce C, Janice K, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc 2004; 52: 417-422.
21. Selim AJ, Berlowitz DR, Fincke G, et al. The health status of elderly veteran enrollees in the Veterans Health Administration. J Am Geriatr Soc 2004; 52: 1271-1276.
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373-383.
23. Joo MJ, Lee TA, Bartle B, et al. Patterns of healthcare utilization by COPD severity: a pilot study. Lung 2008; 186: 307-312.
24. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611-617.
25. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
26. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064.
27. Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12: 462-468.
28. Klungel OH, Edwin PM, Bruce MP, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57: 1223-1231.
29. Stone RA, Obnosky DS, Singer DE, et al. Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. Med Care 1995; 33: AS56-AS66.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
31. Ferguson GT, Antonio A, Richard F, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
32. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
33. Lee TA, Pickard AS; Au DH, Barkle B, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
34. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
35. Barnes NC, Qlu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
36. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621.
37. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
38. Van Overveld FJ, Demkow VA, Górecka D, et al. Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. Eur J Pharmacol 2003; 477: 261-267.
39. Lekkou A, Karakantza M, Mouzaki A, et al. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004; 11: 161-167.
40. Monton C, Rañó A, Torres A. [Inflammatory response in pneumonia]. Archivos de bronconeumol 1998; 34: Suppl. 2, 11-16.
41. Kambas K, Maciej MM, Ioannis AP, et al. C5a and TNF-alpha upregulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008; 180: 7368-7375.
42. Zemans RL, Colgan SP, Downey GP. Trans-epithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 2008; 40: 519-535.
43. Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996; 23: 723-728. (Pubitemid 26331114)
44. Lisboa T, Blot S, Waterer GW, et al. Radiological progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 2009; 135: 165-172.
45. Barbier M, Agustí A, Albertí S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008; 32: 1283-1288.
46. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-647.
47. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10-12.
48. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: a case in against. Eur Respir J 2009; 34: 13-16.
49. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
50. Faustini A, Marino C, D'lppoliti D, et al. The impact on risk-factor analysis of different mortality outcomes in COPD patients. Eur Respir J 2008; 32: 629-636.
51. Mannino DM, Brown C, Giovino GA. Osbtructive lung disease in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997; 156: 814-818.
52. Hansell AL, Walk JA, Soriano JB, et al. What do chronic obstructive pulmonary disease patients die of? A multiple cause coding analysis. Eur Respir J 2003; 22: 809-814.